(MIT Technology Review) – Aurora Therapeutics’ first target is the rare inherited disease phenylketonuria, also known as PKU.

It’s becoming clear that the impact of CRISPR isn’t as big as we all hoped. In fact, there’s a pall of discouragement over the entire field—with some journalists saying the gene-editing revolution has “lost its mojo.”

So what will it take for CRISPR to help more people? A new startup says the answer could be an “umbrella approach” to testing and commercializing treatments. (Read More)